IL2 and renal cell carcinoma: Prior to the early 2000s, systemic therapies demonstrating survival benefit for patients with advanced RCC were limited to interleukin-2 (IL-2) and interferon alpha (IFN-α) that achieved a response in about 20% of patients and carried high toxicity profiles (10).